Wall Street News, AI generated

latest news in clinical trial

Satellos Bioscience Begins Phase 1B Trial for Duchenne Muscular Dystrophy

Satellos Bioscience Begins Phase 1B Trial for Duchenne Muscular Dystrophy

Toronto, Wednesday, 11 December 2024.
Satellos Bioscience has dosed the first participant in their Phase 1B trial of SAT-3247, marking a key step in developing treatments for Duchenne Muscular Dystrophy.

ADC Therapeutics' ZYNLONTA Achieves 94% Response Rate in Lymphoma Trial

ADC Therapeutics' ZYNLONTA Achieves 94% Response Rate in Lymphoma Trial

Lausanne, Wednesday, 11 December 2024.
The LOTIS-7 trial shows ZYNLONTA’s combination with glofitamab achieves a 94% overall response rate in relapsed or refractory diffuse large B-cell lymphoma, presenting promising treatment potential.

Cardiff Oncology's Promising Trial Results in RAS-Mutated Cancer

Cardiff Oncology's Promising Trial Results in RAS-Mutated Cancer

San Diego, Tuesday, 10 December 2024.
Cardiff Oncology reports a 64% response rate in its Phase 2 trial for RAS-mutated colorectal cancer, marking a potential breakthrough in treatment efficacy and safety.